Company intelligence / Profile preview
Cellectis
Paris, Francecellectis.com ↗
- Ownership
- Public · CLLS
- Development stage
- Phase 1
01
Overview
Currently developing multiple clinical programs including UCART22 (Phase 1 for ALL with data expected Q3 2025), UCART20x22 (Phase 1 for r/r NHL with readout expected late 2025), and collaborative programs with AstraZeneca
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- Cell therapyGene therapyCAR T-cell therapyAllogeneic CAR T-cells
- Industry
- Biotech
02
Drug pipeline
22 assets21 more assets in the full pipeline.
Request access →03
Partnerships
04
Financials
- Market cap
- $317.3M
- Total revenue
- $5.2M
- Enterprise value
- $235M
Beyond the preview
Go deeper on Cellectis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cellectis.